Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer

This article reports a rare immune-related cutaneous adverse event (ircAE) manifesting as nasal swelling and ulceration in a patient with small cell lung cancer (SCLC) after treatment with atezolizumab. A patient with extensive-stage SCLC developed symptoms of nasal swelling and ulceration during treatment with atezolizumab combined with anlotinib. Based on clinical test results, we ruled out infections and autoimmune diseases. Histopathological analysis of the lesion biopsy excluded metastatic carcinoma. According to the patient’s medication history, we considered that the nasal swelling and ulceration were extremely rare ircAEs caused by atezolizumab. After we discontinued immunotherapy and administered glucocorticoids, the patient’s nasal skin symptoms improved significantly. We searched multiple medical databases such as PubMed, but did not find similar reports.